EDITORIAL SECTION

Articles

Cybersecurity in Pharma: The Threat No One Budgeted For

There is a particular kind of risk that organisations are bad at pricing the one that has never happened to them Pharmaceutical companies have spent a generation building sophisticated defences against the risks they know intimatelycontamination adulteration deviation recall Quality systems are mature inspectionready and deeply funded Cyber risk has never enjoyed that status It sat in the IT budge...

Unlocking New Therapies: How Generative AI Enhances Drug Discovery

Drug discovery is a highly complex process that used to be very timeconsuming a decade or more for the entire project However Generative AI or Artificial Intelligence has brought significant shifts in the sector

Global CDMO Expansion: Supporting the Growing Advanced Therapy Pipeline

The European advanced therapy sector has spent the better part of two decades proving a scientific point that engineered cells corrected genes and reprogrammed immune systems can deliver durable clinical benefit That argument is now largely settled The question facing pharmaceutical and biotech leadership is industrial rather than scientific whether these therapies can be manufactured consistentl...

Drug Approval Strategies and Regulatory Pathways in the Pharmaceutical Industry

Getting a new medicine to patients is never just a scientific achievement Its also a regulatory one A molecule can be brilliant in the lab and still stall for years if the drug approval process isnt planned properly from day one Thats why across the pharmaceutical industry regulatory strategy has quietly become just as important as clinical data itself

Sustainability in Pharma Manufacturing: A Focus on Green Practices

The pharmaceutical industry is pivotal to global healthcare but its manufacturing processes typically carry a significant environmental burden In recent years there has been an increasing recognition of the importance of sustainability in pharmaceutical manufacturing

Patient-Centric Clinical Trials: Improving Recruitment, Retention, and Diversity

Patientcentricity has spent a decade as a value statement in pharmaceutical annual reports and comparatively little time as an operating discipline That gap is now closing not because the argument became more persuasive but because the economics and the regulatory environment stopped tolerating the alternative

Techno Trends

UGA researchers develop oral drug candidate targeting drug-resistant malaria

Researchers from the University of Georgia UGA and the University of Illinois Chicago have developed a new oral antimalarial drug candidate that could help address drugresistant malaria

Projects

Evonik Launches US$94 Million (EUR 80 million) Biotechnology Expansion in Slovakia

Evonik has commenced construction of a new biotechnology expansion at its Fermas facility in Slovensk upa Slovakia The development is part of an approximately US million investment EUR million

Research Insights

One-month physicochemical stability study of idarubicin prepared in polyolefin-type bags for the treatment of hematological diseases

Idarubicine is a mainstay of the treatment strategy for hematological cancer The literature lacks stability data that comply with current preparation practices and recommendations for conducting stability studies

whitepaper

Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact

For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys